An RNA sequencing study of cells exposed to anlotinib revealed that anlotinib treatment causes downregulation of genes critical for DDR, such as the genes encoding for the DNA polymerase delts proteins (POLDs) that act as response regulators of the DDR, that strongly correlated with SETD1A and Akt expression, suggesting an anti-leukemic activity of anlotinib by targeting SETD1A- and Akt-mediated DNA damage response in MLL-rearranged leukemia cells (Chen et al., 2021). This evidence concerns the gene KMT2A and leukemia.